Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.
Condition: Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer Intervention: Drug: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole) Sponsors: International Cancer Research Group, United Arab Emirates; King Saud University Medical City, Riyadh, Saudi Arabia; Max-Planck-Institut für Quantenoptik (MPQ), and Faculty of Physics at Ludwig-Maximilians-Universität München (LMU), Garching, Germany; King Abdallah University for Scie nce and Technology (KAUST), Thuwal, Saudi Arabia. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 13, 2022 Category: Research Source Type: clinical trials
H (Trastuzumab or Biosimilar) Combined With CDK4/6 Inhibitor + AI ±OFS in the Treatment of HR+HER2+ Advanced Breast Cancer Efficacy and Safety: a Chinese Multi-center Real World Study
Condition: Advanced HR+ HER2 Negative Breast Carcinoma Intervention: Drug: Enituzumab injection+Abesili tablets+Anastrozole tablets Sponsor: Tianjin Medical University Cancer Institute and Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2021 Category: Research Source Type: clinical trials
